Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system

Background: Cholangiocarcinoma (CCA) is a highly lethal and aggressive epithelial tumor of the hepatobiliary system. A poor prognosis, propensity for relapse, low chance of cure and survival are some of its hallmarks. Pemigatinib, the first targeted treatment for CCA in the United States, has been d...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Ran, Li, Liang, Yongchao, Zhang, Yanqiu, An, Zhuoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405447/
https://www.ncbi.nlm.nih.gov/pubmed/37554985
http://dx.doi.org/10.3389/fphar.2023.1194545

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405447/
https://www.ncbi.nlm.nih.gov/pubmed/37554985
http://dx.doi.org/10.3389/fphar.2023.1194545

Ejemplares similares